Washington, D.C. – On June 1, 2021, the Supreme Court of the United States denied Johnson & Johnson’s request for review of the $2.1 billion verdict against the company.
In May 2018, a jury awarded the plaintiffs in Ingham v. Johnson & Johnson a $4.7 billion verdict, which was later reduced by the Missouri Court of Appeals. The Court of Appeals reduced the verdict amount to the final value of $2.1 billion, while otherwise upholding the trial courts’ ruling. Despite the scientific findings in support of this verdict, Johnson & Johnson continues to deny the connection between talc-containing baby powder and ovarian cancer, even though the Company has since halted the sale of their talcum baby powder.
Johnson & Johnson will continue to face litigation, according to The Wall Street Journal, as 28,900 plaintiffs have pending lawsuits against Johnson & Johnson, alleging similar injuries to the plaintiffs in Ingham. The Supreme Court’s decision here concludes the litigation in Ingham, effectively providing relief for the plaintiffs and a path forward for those with pending claims.
Shelby Roden filed one of the first federal Talc lawsuits in the State of Alabama and will continue to monitor the ongoing litigation alleging claims related to ovarian cancer. Please give us a call if you would like more information.
Ingham v. Johnson & Johnson, et al., 608 S.W.3d 663 (Mo. Ct. App. 2020), cert. denied, 593 U.S. _ (U.S. June 1, 2021) (No. 20-1223).